Log in

NASDAQ:NTRPNeurotrope Stock Price, Forecast & News

$1.16
+0.02 (+1.75 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.15
Now: $1.16
$1.20
50-Day Range
$1.14
MA: $1.31
$1.47
52-Week Range
$0.63
Now: $1.16
$7.93
Volume259,025 shs
Average Volume407,174 shs
Market Capitalization$27.46 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Read More
Neurotrope logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.79 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.33 per share

Profitability

Net Income$-15,140,000.00

Miscellaneous

Employees6
Market Cap$27.46 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

How has Neurotrope's stock been impacted by COVID-19 (Coronavirus)?

Neurotrope's stock was trading at $0.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NTRP stock has increased by 33.3% and is now trading at $1.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neurotrope?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Neurotrope.

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Neurotrope.

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) posted its earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.05. View Neurotrope's earnings history.

What price target have analysts set for NTRP?

2 Wall Street analysts have issued twelve-month target prices for Neurotrope's stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Neurotrope's stock price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 13.8%. View analysts' price targets for Neurotrope.

Has Neurotrope been receiving favorable news coverage?

Headlines about NTRP stock have trended negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurotrope earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news about Neurotrope.

Who are some of Neurotrope's key competitors?

What other stocks do shareholders of Neurotrope own?

Who are Neurotrope's key executives?

Neurotrope's management team includes the following people:
  • Dr. Charles S. Ryan, CEO & Director (Age 55)
  • Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
  • Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
  • Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
  • Mr. Jeffrey Benison, Director of Corp. Communications

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $1.16.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $27.46 million. Neurotrope employs 6 workers across the globe.

What is Neurotrope's official website?

The official website for Neurotrope is www.neurotropebioscience.com.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.